The frequency of co-positivity of anti-smooth muscle antibody and anti-nuclear antibodies and their contribution to the diagnosis of autoimmune hepatitis

Abstract

Aim: Autoimmune hepatitis (AIH) is a chronic disease observed especially in women. The International Autoimmune Hepatitis Group recommends scoring systems for diagnosis using clinical and laboratory data. All scoring systems gave points to autoantibodies as anti-nuclear antibody (ANA) and anti-smooth muscle antibody (SMA) positivity. This study investigates the impact of the co-positivity of the ANA and SMA antibodies on the autoimmune hepatitis diagnosis. Material and Method: We monitored 78 autoimmune liver disease (autoimmune hepatitis, AIH) suspected patients with positive SMA antibody and then further tested for ANA between 2014 and2021. SMA test was screened at 1/40 and 1/100 titers and patients who were positive were taken to further dilution. The ANA test was screened at a titer of 1/40 and 1/160, a positive result was found to be repeated with advanced dilutions. All patients’ autoantibody scores of simplified AIH diagnostic system were calculated. Results: Seventy eight patients with positive SMA antibodies screened for ANA test with 1/40 and 1/160 titer, only 2 patients was found to be negative. The most frequently observed ANA pattern is cytoplasmic linear fibrils (68% ). The 95% ANA positive results was examined at a screening titer of 1/160. The 95% SMA positive results was found at a screening titer of 1/100. The autoantibody scores of 76 patients were +2, patient’s scores were +1. Conclusion: SMA antibody positivity is accompanied by a high rate of ANA antibody positivity but the co-positivity didn’t effect diagnostic score systems. On the other the co-positivity could be a sign of another associated autoimmune diseases.

Keywords

• anti-smooth muscle antibody
• anti-nuclear antibodies
• autoimmune hepatitis

References

1. Manns M, Lohse AW, Vergani D. Autoimmune hepatitis – Update 2015. Journal of Hepatology 2015; 62: 100– 11.
2. Waldenstrom J. Liver, blood proteins and food proteins. DTSH Z Verdau Stoffwechselkr 1952; 12: 113- 21.
3. Mackay JR, Taft LI, Crowling DC. Lupoid hepatitis. Lancet 1956; 271: 1323- 6.
4. Kirk AP, Jain S, Pocock S, Thomas HC, Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. GUT 1980; 21: 78- 63.
5. Muratori P, Granito A, Quarneti C, et al. Autoimmune hepatitis in Italy: the Bologna experience. J Hepatol 2009; 50: 1210- 8.
6. Liberal R, Longhi ms, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 653- 64.
7. Donaldson PT. Genetics of liver diease: immunogenetics and disease pathogenesis. Gut 2004; 53: 599- 608.
8. Alvarez F, Berg PA, Bianchi L, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929- 38.

9. Ma Y, Bogdanos DP, Hussain MJ, et al. Poly-clonal T-cell responce to cytochrome P45OID6 are associated with disease activity in autoimmune hepatitis type2. Gastroenterology 2006; 130: 868- 82.
10. Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology 2020; 72: 671- 722.
11. Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. Population based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One 2017; 12: e0182391.
12. Takahashi A, Arinaga-Hino T, Ohira H, et al. Autoimmune hepatitis in Japan: trends in a nationwide survey. J Gastroenterol 2017; 52: 631- 40.
13. Tanaka A, Mori M, Matsumoto K, Ohira H, Tazuma S, Takikawa H. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan. Hepatol Res 2019; 49: 881- 9.
14. Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol 2001; 16: 1384- 9.
15. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002; 97: 2402- 7.
16. Werner M, Prytz H, Ohlsson B, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008; 43: 1232- 40.
17. Gerenli N, Çeltik Ç. Mode of presentation and association of autoimmune diseases in children with autoimmune hepatitis. Genel Tıp Derg 2022: 32: 95- 101.
18. Gölçe S, Durmaz Ö, Çeltik Ç et al. Atipik Celiac Hastası ve eşlik eden otoimmun hepatit. Balkan Med J 2009: 3: 273- 276.
19. Gencdal G, Meral C, Azarsız E, et al. Prevalence of coeliac disease in autoimmune liver disease and priamry biliary cholangitis. Çağdaş Tıp Derg 2018: 8: 295- 8.
20. Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014; 73: 17–23.
21. Damoiseaux J, Mühlen C, Torre I, et al. International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. Autoimmune Highlights 2016; 7: 1- 8.
22. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheu. 2002; 47: 434– 44.
23. Chan E.K.L., Damoiseaux J, de Melo Cruvinel, et al. Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. Lupus 2016; 25: 797- 804.
24. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010; 69: 1420– 2.